CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Idiopathic pulmonary arterial hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, characterized by pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) increase due to pronounced remodeling of small pulmonary arteries and arterioles, with progressive deterior...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2015-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/5655 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849244362435723264 |
|---|---|
| author | T. V. Martynyuk M. A. Saidova N. M. Danilov V. K. Lazutkina I. Ye. Chazova |
| author_facet | T. V. Martynyuk M. A. Saidova N. M. Danilov V. K. Lazutkina I. Ye. Chazova |
| author_sort | T. V. Martynyuk |
| collection | DOAJ |
| description | Idiopathic pulmonary arterial hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, characterized by pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) increase due to pronounced remodeling of small pulmonary arteries and arterioles, with progressive deterioration and the rapid development of right ventricle failure. The key pathogenetic feature is the endothelial dysfunction, which leads to the development of vasoconstriction, thrombosis in situ, proliferative and inflammatory changes in the lung microvasculature. Optimization of drug therapy is associated with the clinical implementation of highly effective pathogenetic drugs which act on the main disease targets - activation of endothelin-1 (ET-1) system, the lack of endogenous prostacyclin and nitric oxide. The role of ET-1 as a powerful vasoconstrictor that induces cell proliferation and differentiation, production of cytokines, growth factors, biologically active substances. Endothelin receptor antagonists (ERA) represents the important class of PAH-specific therapy, including two non-selective ERAs-nonselective bosentan and selective ambrizentan. Presented clinical case demonstrates the long-term reliable efficacy and safety of ambrizentan for 10 years in the IPAH patient with the baseline functional class III (WHO). |
| format | Article |
| id | doaj-art-259fc0a6110245f3a135f9cb18ea29ef |
| institution | Kabale University |
| issn | 2225-1685 2305-0748 |
| language | Russian |
| publishDate | 2015-12-01 |
| publisher | InterMedservice |
| record_format | Article |
| series | Евразийский Кардиологический Журнал |
| spelling | doaj-art-259fc0a6110245f3a135f9cb18ea29ef2025-08-20T03:59:12ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482015-12-0104485510.38109/2225-1685-2015-4-48-555652CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSIONT. V. Martynyuk0M. A. Saidova1N. M. Danilov2V. K. Lazutkina3I. Ye. Chazova4Russian cardiological research and production complex Ministry of HealthRussian cardiological research and production complex Ministry of HealthRussian cardiological research and production complex Ministry of HealthRussian cardiological research and production complex Ministry of HealthRussian cardiological research and production complex Ministry of HealthIdiopathic pulmonary arterial hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, characterized by pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) increase due to pronounced remodeling of small pulmonary arteries and arterioles, with progressive deterioration and the rapid development of right ventricle failure. The key pathogenetic feature is the endothelial dysfunction, which leads to the development of vasoconstriction, thrombosis in situ, proliferative and inflammatory changes in the lung microvasculature. Optimization of drug therapy is associated with the clinical implementation of highly effective pathogenetic drugs which act on the main disease targets - activation of endothelin-1 (ET-1) system, the lack of endogenous prostacyclin and nitric oxide. The role of ET-1 as a powerful vasoconstrictor that induces cell proliferation and differentiation, production of cytokines, growth factors, biologically active substances. Endothelin receptor antagonists (ERA) represents the important class of PAH-specific therapy, including two non-selective ERAs-nonselective bosentan and selective ambrizentan. Presented clinical case demonstrates the long-term reliable efficacy and safety of ambrizentan for 10 years in the IPAH patient with the baseline functional class III (WHO).https://www.heartj.asia/jour/article/view/5655idiopathic pulmonary hypertensionendothelin-1endothelin receptor antagonistsambrisentanидиопатическая лёгочная гипертензияэндотелин-1антагонисты рецепторов эндотелинаамбризентан |
| spellingShingle | T. V. Martynyuk M. A. Saidova N. M. Danilov V. K. Lazutkina I. Ye. Chazova CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION Евразийский Кардиологический Журнал idiopathic pulmonary hypertension endothelin-1 endothelin receptor antagonists ambrisentan идиопатическая лёгочная гипертензия эндотелин-1 антагонисты рецепторов эндотелина амбризентан |
| title | CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION |
| title_full | CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION |
| title_fullStr | CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION |
| title_full_unstemmed | CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION |
| title_short | CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION |
| title_sort | clinical case of successful 10 year ambrizentan treatment of the patient with idiopathic pulmonary arterial hypertension |
| topic | idiopathic pulmonary hypertension endothelin-1 endothelin receptor antagonists ambrisentan идиопатическая лёгочная гипертензия эндотелин-1 антагонисты рецепторов эндотелина амбризентан |
| url | https://www.heartj.asia/jour/article/view/5655 |
| work_keys_str_mv | AT tvmartynyuk clinicalcaseofsuccessful10yearambrizentantreatmentofthepatientwithidiopathicpulmonaryarterialhypertension AT masaidova clinicalcaseofsuccessful10yearambrizentantreatmentofthepatientwithidiopathicpulmonaryarterialhypertension AT nmdanilov clinicalcaseofsuccessful10yearambrizentantreatmentofthepatientwithidiopathicpulmonaryarterialhypertension AT vklazutkina clinicalcaseofsuccessful10yearambrizentantreatmentofthepatientwithidiopathicpulmonaryarterialhypertension AT iyechazova clinicalcaseofsuccessful10yearambrizentantreatmentofthepatientwithidiopathicpulmonaryarterialhypertension |